ObjectivesThis study aimed to assess the prevalence, the change, and the determinants of change in polypharmacy in a population-based sample.MethodsBaseline (2003–2006) and follow-up (2009–2012) data are from 4679 participants aged… Click to show full abstract
ObjectivesThis study aimed to assess the prevalence, the change, and the determinants of change in polypharmacy in a population-based sample.MethodsBaseline (2003–2006) and follow-up (2009–2012) data are from 4679 participants aged between 35 and 75 years (53.5% women, mean age 52.6 ± 10.6 years) from the population of Lausanne, Switzerland. Polypharmacy was defined by the regular use of ≥5 drugs. Four categories of change were defined: never (no polypharmacy at baseline and follow-up), initiating (no polypharmacy at baseline but at follow-up), maintaining, or quitting.ResultsPolypharmacy increased from 7.7% at baseline to 15.3% at follow-up. Cardiovascular drugs were the most prescribed medicines at baseline and follow-up. Gender, age, obesity, smoking, previously diagnosed hypertension, or diabetes or dyslipidemia were significantly and independently associated with initiating and maintaining polypharmacy.ConclusionIn a population-based sample, prevalence of polypharmacy doubled over a 5.6-year period. The main determinants of initiating polypharmacy were age, overweight and obesity, smoking status, and previously diagnosed cardiovascular risk factors.
               
Click one of the above tabs to view related content.